Can you shortly describe the research topics included in your SIG?
This group brings together researchers who focus on the development and implementation of biomarkers associated with neurodegenerative disorders and other conditions of the brain. Mediums like CSF, blood, skin biopsies, and cells are of interest. We use MultiPark’s platforms for analysis, such as SIMOA, Mass spect, Mesoscale discovery, FACS, and ELISAs, but also novel technology development (nanotech) for isolating biomarkers.
Which of MultiPark’s strategic goals does it best align with?
Using fluid biomarkers is a way to develop accurate and cost-effective diagnostics using minimally invasive methods. Biomarkers can be used for as screening tools for selecting individuals suitable for specific interventions within clinical trials and to help patients to get appropriate therapies in time (personalized medicine).
What are your overarching goals?
Our vision is to link biomarker analysis to pathophysiology in neurodegeneration. This is crucial in order to understand disease mechanisms and for the detection, monitoring and prognosis of neurodegenerative disorders. Establish novel technologies for isolating biomarkers in relevant biofluids linked to neurodegenerative diseases is another goal we have. We also aim to accelerate scientific discoveries in the field of biomarkers by detection of synergies, increased collaborations and translation/implementation of new methods into the clinic.
What activities do you plan?
Once a year, the group plans to organize workshops or symposia on techniques and/or use of biomarkers.
How many early-career researchers are affiliated with this SIG?
28 Ph.D students and 22 postdocs at the moment.
How do you think that early-career researchers can contribute to the SIG?
They will contribute with data analysis and lab work.
